$PATH

PATH Stock Slips As UBS Trims Price Target

UiPath (PATH) shares were up about 7.3% on AI automation optimism, but UBS cut its price target to $12 from $13 while keeping a Neutral rating. Street consensus remains Hold with a mean target near $13.47 versus a price around $10.81. The article also cites UiPath’s annual revenue of about $1.61B and recent quarterly net income of about $22.5M.

Original reporting
Published Jul 27, 2026, 8:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PATH Stock Slips As UBS Trims Price Target — source image
Decision brief

The 30-second read

$PATHNeutralMed
01

Why it matters

The UBS target reduction from $13 to $12, alongside a Hold consensus and mean target near $13.47, suggests limited upside and supports a tactical focus on support near $10 and supply around $12 to $12.50.

02

Market read

A single analyst target trim is a sentiment and positioning catalyst, likely reinforcing range trading rather than triggering a trend reversal.

03

What to watch

The piece emphasizes price levels and range behavior but does not provide new company-specific guidance, so the market may revert to fundamentals if no further downgrades follow.

Relevance 7/10Novelty 5/10Timing: after-hours/overnight analyst target cut framing for the next trading sessions

Background

UiPath is described as trading higher on upbeat AI automation sentiment, while UBS trims its target and keeps Neutral.

Company-level read

Ticker impact

$PATHNeutralMedium confidence
Context

UBS cut UiPath’s price target from $13 to $12 while keeping a Neutral stance, tempering expectations for PATH near $10.81.

Expected impact

Near-term downside risk is modest, with follow-through more likely if price breaks below the cited $10 support; otherwise expect consolidation.

Evidence & confidence

The article’s actionable catalyst is the UBS target reduction and reiterated Neutral rating, which typically shifts sentiment but is not a fundamental reset like earnings or guidance.

Market effects

Signals that AI automation software names may face more valuation discipline, even with profitability and cash flow improving.

Primarily US-listed sentiment impact; no direct regional macro linkage is provided.

Limited global spillover; the catalyst is a single-bank target change rather than a sector-wide regulatory or earnings event.

Counterpoint

Despite the target cut, the article highlights profitability, high gross margins, and free cash flow, which can support dips and attract dip-buyers.

Key entities

  • UiPath Inc.

    Subject of the article; UBS lowered its price target and reiterated Neutral.

  • UBS

    Issued the price target cut from $13 to $12 while maintaining Neutral.

Related articles

$PLTRHighAI 9/10

Palantir Rockets 16% After Q2 Blowout; C3.ai, UiPath Sit Out the Rally

Palantir Technologies reported Q2 2026 revenue of $1.94B, up 92.8% YoY, beating $1.81B consensus, and raised FY2026 revenue guidance to about $8.15B. U.S. commercial total contract value reached a record $2.1B. Shares rose about 16% to $145.50 after Deutsche Bank upgraded to Buy with a $200 target; C3.ai and UiPath did not rally.

$PLTRMed

JFrog, Zscaler, Palo Alto Networks, Shopify, and UiPath Shares Are Soaring, What You Need To Know

In Tuesday premarket trading, Palantir’s (PLTR) reported Q2 results and raised full-year revenue outlook drove a broad rally in enterprise software and cybersecurity peers. The article cites Palantir’s 26% jump and links the move to lower Treasury yields after geopolitical de-escalation. It also lists gains for JFrog (FROG), Zscaler (ZS), Palo Alto Networks (PANW), Shopify (SHOP), and UiPath (PATH).

$PATHMed

UiPath (NYSE:PATH) Shares Fall as Q2 Outlook Indicates Reduced ARR Growth

NEW YORK, July 30, 2026, 2:01 p.m. EDT — Shares of UiPath NYSE:PATH declined after the company forecasted slower additions to annualized recurring revenue for the second quarter. The stock dropped 3.3% to $12.18 in early U.S. trading. Initial estimates indicate Q2 guidance suggests net new ARR between $28 million and $33 million. Initial estimate: market value, adjusted for cash, is approximately 2.8 times the projected revenue for fiscal 2027. UiPath shares declined even as U.S.

$PATHMed

UiPath shares rebound as Wall Street warms to its AI-agent pivot

UiPath shares rebounded about 15% over five days after the company reported its first-quarter GAAP operating profit of $28m and GAAP profit for the first time in a first quarter, following a loss a year earlier. Revenue rose 17% to $418m; annual recurring revenue reached $1.9bn (+12%). UiPath is pivoting to AI agents, including its WorkFusion acquisition.

$PATHMedAI 9/10

Stock Market Today, June 1: Stock Market Today, June 1: UiPath Rises After Strong Q1 Results and Raised Outlook

UiPath (NYSE:PATH) rose 11.77% to close at $13.10 after reporting fiscal Q1 2027 results and raising guidance, according to the company. The report cited 17% year-over-year revenue growth to $418 million, annual recurring revenue of $1.901 billion (+12%), and positive GAAP operating income of $28 million. Trading volume was 65.5 million shares.

$ESTCMedAI 9/10

Morgan Stanley slashes targets on 3 software stocks after earnings

Morgan Stanley cut price targets on Elastic, UiPath and PagerDuty after their earnings, citing uneven AI impact across software. For Elastic, it kept Equal Weight and lowered the target to $73 from $80; Q4 remaining performance obligations rose 20% to $1.2B and RPO 27% to $1.98B. For UiPath, target fell to $15 from $17; FY2027 ARR guidance was $2.058B–$2.063B. PagerDuty target was cut to $7 from $10.